Evaluation of PPAR-γ with lipid profiles and blood glucose in obese persons with DM type 2 and obese persons without DM type 2

Manish Malhotra; Faruque Ahmed

doi:10.53730/ijhs.v6nS3.5466

Authors

Manish Malhotra Associate Professor, Department of Biochemistry, Sri Ram Murti Smarak Institute of Medical Science, Bhojipura, Bareilly, Uttar Pradesh, India
Faruque Ahmed Assistant Professor, Department of Biochemistry, I Q City Medical College & Hospital, Durgapur, West Bengal, India

Keywords:

PPAR-γ, lipid profiles, blood glucose, DM type 2

Abstract

PPAR-γ is expressed at high levels in adipose tissue and is a central regulator of adipocyte gene expression and differentiation. PPAR-γ is induced during adipocyte differentiation, and retroviral expression of PPAR-γ stimulates adipose differentiation of cultured fibroblasts. Several studies demonstrate that PPAR-γ is both necessary and sufficient to promote differentiation of fat cells both in vivo and in vitro. The present study has been conducted at the Department of Biochemistry, Shri Ram Murti Smark Institute of Medical Sciences (SRMS IMS), Bareilly U.P. India. Among 30 Adult normal persons, 30 Adult obese persons without DM type 2 and 30 Adult obese persons with DM type 2 were selected for the study. BMI was measured for each subject and proposed biochemical parameters were estimated in their blood samples. The Subject chosen were not on any drug treatment during days of blood collection. Age of the subject was between 25-65 years. For the present study 30 normal (control) and 60 obese cases were taken. Out of 60 obese cases, 30 were found to be without DM Type-2 and 30 cases with DM Type-2.

Downloads

Download data is not yet available.

References

Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI: n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 2007, 56(4):1034–1041.

Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B: Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 2000, 471(1):34–38.

Rao MS, Kashireddy P, Musunuri S, Okonkwo A: Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisomeproliferatoractivated receptor alpha ligand in rats. In Vivo 2002, 16(2):145–152.

Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11(6):779–791.

Margeli A, Kouraklis G, Theocharis S: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 2003, 6(3):165–169.

Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000, 2(4):327–335.

Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409–435.

Boitier E, Gautier JC, Roberts R: Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol 2003, 2(1):3.

Rogue A, Lambert C, Jossé R, Antherieu S, Spire C, Claude N, Guillouzo A: Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. PLoS One 2011, 6(4):e18816.

Rogue A, Spire C, Brun M, Claude N, Guillouzo A: Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010, 2010:325183.

Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005, 67(1):15–19.

Sheu SH, Kaya T, Waxman DJ, Vajda S: Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry (Mosc) 2005, 44(4):1193–1209.

Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GSH, Lopez M, Seppänen-Laakso T, Ashcroft FM, Orešič M, Vidal-Puig A: PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007, 3(4):e64.

Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisomeproliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113(2):159–170.

Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527–550.

Viswakarma N, Jia Y, Bai L, Vluggens A, Borensztajn J, Xu J, Reddy JK: Coactivators in PPAR-regulated gene expression. PPAR Res 2010, 2010:2050126.

Heikkinen S, Auwerx J, Argmann CA: PPARγ in human and mouse physiology. Biochim Biophys Acta 2007, 1771(8):999–1013.

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs:peroxisome proliferator-activated receptors are nuclearreceptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45(2):120–159.

Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS: PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002, 16(1):27–32.

Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and −2 isoforms and influence of insulin. J Biol Chem 1997, 272(32):20230–20235.

Sertznig P, Seifert M, Tilgen W, Reichrath J: Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 2007, 212(1):1–12.